Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · H.B. Fuller (FUL)

H.B. Fuller Adds Celine Martin, Former J&J MedTech Executive, to Board Effective Dec. 1

Neutral Impact 2 of 5 leadership Written later

H.B. Fuller elected Celine Martin, a former Johnson & Johnson MedTech group chairman, as a Class III director effective December 1, 2025. The company said her medical industry experience supports its focus on high-margin medical markets and its goal of a greater than 20% EBITDA margin.

Key points

  • Celine Martin, age 51, elected by the Board on October 2, 2025, effective December 1, 2025; term expires at the 2026 annual meeting
  • Serves on the Audit and Compensation Committees; receives $100,000 annual cash retainer, initial grant of 1,300 restricted stock units, and eligibility for a $165,000 annual phantom stock grant
  • Board will have nine directors after December 1, 2025, eight of whom are independent

The filing

CompanyH.B. Fuller (FUL)
Form8-K, current report
Filed with the SECOct 8, 2025, 8:15 AM ET
Accession number0001437749-25-030677

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:49 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 08, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.